FIELD: pharmaceutics.
SUBSTANCE: present invention relates to novel cationic lipid of formula A or its any pharmaceutically acceptable salt, which are used to generate lipid nanoparticles (LNP) for delivery of oligonucleotides, to composition of lipid nanoparticles (LNP) containing disclosed cationic lipid and to use of cationic lipid. In formula A values R1, R2, R3, R', Rʺ, n, L1 and L2 are such as specified in patent claim.
EFFECT: novel low-molecular cationic lipids for delivery of oligonucleotides are described.
10 cl, 14 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | 2011 |
|
RU2624045C2 |
| TRIALKYL CATIONIC LIPIDS AND METHODS FOR USING THEM | 2013 |
|
RU2718053C2 |
| LIPID COMPOUND AND COMPOSITION BASED THEREON | 2021 |
|
RU2825571C1 |
| LIPID PARTICLES CONTAINING NUCLEIC ACIDS AND RELATED METHODS | 2010 |
|
RU2573409C2 |
| LIPID NANOPARTICLES FOR IN VIVO MEDICINAL PRODUCTS DELIVERY AND THEIR USE | 2020 |
|
RU2799045C1 |
| IMPROVED METHOD OF PRODUCING LIPID NANOPARTICLES LOADED WITH MRNA | 2020 |
|
RU2832672C2 |
| COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | 2018 |
|
RU2798342C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING DOUBLE-STRANDED RIBONUCLEIC ACID INHIBITING EXPRESSION OF COMPLEMENT COMPONENT C5 | 2020 |
|
RU2833504C1 |
| FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | 2018 |
|
RU2808990C2 |
| PEGYLATED LIPOSOMES FOR IMMUNOUGEN-CODING RNA DELIVERY | 2012 |
|
RU2628705C2 |
